ChemoCentryx Inc. (CCXI) Stock Price Up 10.4%
ChemoCentryx Inc. (NASDAQ:CCXI) shares rose 10.4% during trading on Tuesday . The stock traded as high as $5.17 and last traded at $5.11, with a volume of 276,654 shares. The stock had previously closed at $4.63.
Separately, JPMorgan Chase & Co. reiterated a “buy” rating and set a $11.00 price target on shares of ChemoCentryx in a report on Tuesday, August 9th.
The stock has a 50 day moving average price of $4.57 and a 200 day moving average price of $3.97. The firm’s market capitalization is $240.00 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/chemocentryx-inc-ccxi-stock-price-up-10-4.html
Hedge funds and other institutional investors have recently made changes to their positions in the company. Geduld E E acquired a new position in shares of ChemoCentryx during the second quarter worth $112,000. Landscape Capital Management L.L.C. acquired a new position in shares of ChemoCentryx during the first quarter worth $113,000. Alliancebernstein L.P. acquired a new position in shares of ChemoCentryx during the second quarter worth $142,000. Bank of Montreal Can acquired a new position in shares of ChemoCentryx during the second quarter worth $144,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of ChemoCentryx during the second quarter worth $155,000. 47.79% of the stock is currently owned by hedge funds and other institutional investors.
ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.